Acilog 100 IU/3 ml vial Injection

Acilog 100 IU/3ml – Insulin Aspart Injection by ACI Limited

What is Acilog?

Acilog is a rapid-acting insulin aspart analogue manufactured by ACI Limited, one of Bangladesh's most trusted pharmaceutical companies. Containing 100 IU/ml insulin aspart, it provides fast post-meal glucose control with an onset of 10–20 minutes — significantly faster than regular human insulin (onset 30 min). Acilog is designed for mealtime bolus use and can be injected immediately before or shortly after meals, offering greater lifestyle flexibility. ACI Limited produces the Acilog range in multiple formats: the 3 ml vial, the Acilog Biopen (pre-filled disposable pen), and the biphasic Acilog Mix 30/70 (combining rapid aspart with intermediate-acting protamine aspart) — covering both bolus and premixed insulin needs from a single trusted local manufacturer.

Generic Name and Composition

Each ml: 100 IU insulin aspart (rDNA). Insulin aspart is a rapid-acting analogue of human insulin where the B28 proline is replaced by aspartic acid. This substitution prevents hexamer self-association, enabling rapid absorption of monomers after SC injection. The result is an onset of 10–20 minutes, a peak at 1–3 hours, and a total duration of 3–5 hours — ideal for matching the glucose excursion from meals.

Indications

• Type 1 diabetes — bolus component in basal-bolus regimen
• Type 2 diabetes — mealtime bolus insulin to control post-prandial glucose
• Insulin pump (CSII) therapy
• Patients requiring affordable, locally manufactured rapid-acting insulin analogue

How It Works — Mechanism of Action

Following SC injection, aspart monomers are rapidly absorbed into the bloodstream (onset 10–20 min). Peak insulin levels are achieved in 1–3 hours, coinciding with the peak glucose absorption from a meal. Acilog activates insulin receptors: stimulates GLUT-4 glucose uptake in muscle and adipose tissue, suppresses hepatic glucose output, and promotes glycogen synthesis — rapidly controlling post-meal glucose spikes. The short duration of 3–5 hours minimises late post-prandial hypoglycaemia.

Dosage and Administration

Inject 0–10 minutes before meals; may be given immediately after if post-meal injection is needed. Type 1: Individualised dose matched to carbohydrate intake. Type 2: Start 4–6 IU before main meals; titrate based on 2-hour post-meal glucose. Inject SC into abdomen (fastest absorption), thigh, or upper arm. Rotate injection sites within the same region.

Side Effects

Very common: Hypoglycaemia (especially if meal is delayed after injection). Common: Injection site reactions, lipohypertrophy, weight gain. Uncommon: Lipoatrophy, peripheral oedema, visual changes at initiation. Rare: Generalised hypersensitivity, anaphylaxis.

Drug Interactions

Enhance effect: OADs, GLP-1 agonists, SGLT-2 inhibitors, ACE inhibitors, MAO inhibitors, salicylates, alcohol. Reduce effect: Corticosteroids, glucagon, thyroid hormones, sympathomimetics, thiazides, oral contraceptives. Mask symptoms: Beta-blockers, clonidine.

Contraindications

• Hypersensitivity to insulin aspart or any excipient
• Active hypoglycaemia; do not administer IV except under medical supervision

Pregnancy and Lactation

Pregnancy: Insulin aspart is considered safe in pregnancy; specialist monitoring required. Lactation: No clinically significant breast milk transfer expected.

Precautions and Warnings

• Always eat a meal within 10 minutes of injection — delayed meals after Acilog injection significantly increase hypoglycaemia risk.
• Acilog is a clear solution — discard if cloudy, particulate, or discoloured.
• Combine with a basal insulin (e.g., Larsulin/Glarine/Vibrenta) in Type 1 diabetes.
• Do not freeze. Protect from light and heat.

Overdose

Hypoglycaemia. Mild: oral glucose. Severe: IV dextrose or IM glucagon 1 mg. Acilog's short duration (3–5 hrs) limits prolonged hypoglycaemia risk, but glucose monitoring is still essential.

Storage Instructions

• Unopened: 2–8 degrees C. Do not freeze.
• In-use vial: Below 25 degrees C. Protect from light.
• Discard 28 days after first use.

Frequently Asked Questions

Q1: What is the difference between Acilog and Acilog Mix?
Acilog contains pure insulin aspart (rapid-acting only) — used as bolus mealtime insulin. Acilog Mix 30/70 contains 30% soluble insulin aspart + 70% protamine insulin aspart crystals (intermediate-acting) — a premixed formulation for twice-daily use that covers both post-meal and basal needs without a separate basal injection.

Q2: Is Acilog the same as NovoRapid or Glyset R?
All contain insulin aspart 100 IU/ml. NovoRapid is the originator (Novo Nordisk, Denmark). Acilog (ACI Limited) and Glyset R are locally manufactured biosimilars with equivalent pharmacology. Choice depends on availability, cost, and physician/patient preference.

Q3: Why is Acilog faster than regular human insulin (Humulin R, Diasulin R)?
Regular human insulin forms hexamers that must dissociate before absorption — causing a 30-min onset delay. Insulin aspart's B28 mutation prevents stable hexamer formation, allowing rapid monomer absorption immediately after injection — giving a 10–20 min onset.

Q4: Who manufactures Acilog?
ACI Limited, Bangladesh — a leading Bangladeshi pharmaceutical conglomerate producing a wide range of medicines including the Acilog insulin range (Acilog vial, Biopen, and Acilog Mix 30/70).

Medical Disclaimer: For educational purposes only. Acilog is Rx-only. Consult your diabetologist before starting or changing insulin therapy. DiabetesStore.com.bd is a licensed online pharmacy in Bangladesh.